NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

BLUE

Bluebird bio Inc

May 16 • 04:00PM ET

4.97

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN ALNY RGEN IONS SGMO CLLS NTLA EDIT

| Held by: VTI VXF FESM VTWO VTWV BTEC MEDX VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-20.61	Insider Own	1.08%	Shs Outstand	9.79M	Perf Week	42.00%
Market Cap	48.67M	Forward P/E	-	EPS next Y	-1.74	Insider Trans	-5.76%	Shs Float	9.69M	Perf Month	19.76%
Income	-199.98M	PEG	-	EPS next Q	-3.69	Inst Own	37.44%	Short Float	4.42%	Perf Quarter	-31.64%
Sales	103.95M	P/S	0.47	EPS this Y	56.52%	Inst Trans	-2.23%	Short Ratio	0.70	Perf Half Y	-36.38%
Book/sh	-5.91	P/B	-	EPS next Y	84.94%	ROA	-43.13%	Short Interest	0.43M	Perf Year	-76.78%
Cash/sh	8.04	P/C	0.62	EPS next 5Y	36.36%	ROE	-546.55%	52W Range	3.20 - 28.60	Perf YTD	-40.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.66%	ROI	-	52W High	-82.62%	Beta	0.33
Dividend TTM	-	Quick Ratio	0.29	Sales past 5Y	160.48%	Gross Margin	12.27%	52W Low	55.31%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	0.55	EPS Y/Y TTM	56.94%	Oper. Margin	-202.52%	RSI (14)	63.53	Volatility	2.90% 5.44%
Employees	248	Debt/Eq	-	Sales Y/Y TTM	127.51%	Profit Margin	-192.39%	Recom	2.67	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.76%	Payout	-	Rel Volume	0.95	Prev Close	4.97
Sales Surprise	-7.27%	EPS Surprise	3.50%	Sales Q/Q	108.43%	Earnings	Feb 25	Avg Volume	615.12K	Price	4.97
SMA20	22.31%	SMA50	18.13%	SMA200	-40.06%	Trades		Volume	582,618	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Upgrade	JP Morgan	Underweight → Neutral
Nov-15-24	Downgrade	JP Morgan	Neutral → Underweight
Nov-15-24	Downgrade	BofA Securities	Buy → Neutral	$3 → $0.50
Aug-15-24	Downgrade	JP Morgan	Overweight → Neutral
Dec-11-23	Downgrade	HSBC Securities	Hold → Reduce
Dec-08-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$3 → $7
Oct-17-23	Initiated	Cantor Fitzgerald	Neutral
Sep-06-23	Initiated	HSBC Securities	Buy	$4.21
Jul-19-23	Upgrade	BofA Securities	Neutral → Buy	$6 → $10
Jun-01-23	Upgrade	Barclays	Equal Weight → Overweight	$7 → $8
Apr-28-23	Initiated	JP Morgan	Overweight	$7
Mar-07-23	Initiated	Robert W. Baird	Outperform	$10
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform	$8
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight	$4
Nov-08-21	Reiterated	Wells Fargo	Equal Weight	$25 → $16
Nov-08-21	Reiterated	Wedbush	Neutral	$22 → $11
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform	$26 → $14
Nov-08-21	Reiterated	Canaccord Genuity	Hold	$20 → $15

Show Previous Ratings

May-16-25 04:30PM	Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions (Business Wire)
May-14-25 06:55PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +50.45%
06:00PM	Bluebird: Q1 Earnings Snapshot (Associated Press Finance)
01:27PM	Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity (Benzinga)
08:30AM	Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement (Business Wire)
08:30AM	Loading…
May-09-25 08:30AM	Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital (Business Wire) -5.66%
May-05-25 04:00PM	Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio (Business Wire)
Apr-16-25 08:00AM	bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement (Business Wire) -7.16%
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
Mar-28-25 04:15PM	bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid (Business Wire) +7.65% +19.61%
Mar-27-25 06:25PM	Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-22-25 06:46AM	What Moved Markets This Week (SeekingAlpha)
Feb-21-25 01:22PM	Struggling bluebird bio to go private for less than $30m (Pharmaceutical Technology) -42.05%
08:53AM	What's Going On With Gene Therapy Company Bluebird Bio Stock Today? (Benzinga)
07:30AM	bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital (Business Wire)
06:07AM	Loading…
Dec-29-24 06:07AM	bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-08-24 12:30PM	bluebird bio Presents Positive Long-Term Data On LYFGENIA (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Dec-07-24 12:00PM	Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-04-24 04:05PM	bluebird bio Announces 1-for-20 Reverse Stock Split (Business Wire) +105.38% -39.73%
08:47AM	bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model (Business Wire)
Nov-29-24 08:07AM	FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy (Benzinga) +7.20%
Nov-15-24 02:05PM	JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options (Benzinga) -11.53%
02:07AM	bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Nov-14-24 08:10AM	Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:08AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire)
Nov-06-24 04:15PM	bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call (Business Wire) -13.04%
Nov-05-24 09:05AM	bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-31-24 03:48AM	bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies (Insider Monkey) -5.07%
Oct-11-24 09:09AM	Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy (Benzinga)
01:22PM	Loading…
Oct-10-24 01:22PM	Bluebird bios Skysona led to seven cases of blood cancer in gene therapy trials (Pharmaceutical Technology)
Oct-04-24 04:05PM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.04% -8.67%
Sep-27-24 04:40PM	Bluebird: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing (Business Wire)
Sep-24-24 12:14PM	Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year (Benzinga)
07:00AM	bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 (Business Wire)
Sep-13-24 05:16PM	Bluebird: Q1 Earnings Snapshot (Associated Press Finance) +5.54%
04:41PM	bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q (Business Wire)
Aug-28-24 09:13AM	FDA will not meet ahead of bluebird bios sickle cell disease gene therapy PDUFA date (Pharmaceutical Technology)
08:00AM	bluebird bio Announces September Investor Events (Business Wire)
Aug-23-24 04:05PM	bluebird bio Announces Receipt of Expected Notices from Nasdaq (Business Wire)
Aug-14-24 07:00AM	bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -23.12%
Aug-12-24 08:00AM	bluebird bio Announces Second Quarter 2024 Results Call Date (Business Wire)
Aug-02-24 04:05PM	bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.81%
Jul-23-24 01:54PM	HHS gives thumbs down to bluebirds fertility support programme (Pharmaceutical Technology) +8.77%
Jul-03-24 04:05PM	bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-02-24 10:15PM	2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner (PR Newswire)
May-29-24 07:00AM	bluebird bio Appoints O. James Sterling as Chief Financial Officer (Business Wire)
May-17-24 03:46PM	BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions? (TipRanks)
May-16-24 09:22AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
May-14-24 11:24AM	Shareholders of bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights BLUE (GlobeNewswire)
May-10-24 03:36PM	bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ... (GuruFocus.com) -5.36%
01:34PM	bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well (Zacks)
May-09-24 07:00AM	bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire) +14.92%
May-07-24 12:40PM	bluebird bio, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights BLUE (GlobeNewswire)
May-06-24 07:05AM	bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events (Business Wire) +11.14%
07:00AM	bluebird bio Announces Completion of First Cell Collection for LYFGENIA Gene Therapy (Business Wire)
Apr-26-24 04:43PM	bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report (MT Newswires)
04:05PM	bluebird bio Announces Receipt of Expected Notice from Nasdaq (Business Wire)
Apr-16-24 02:05PM	bluebird (BLUE) Underperforms Industry YTD Amid Challenges (Zacks)
Apr-15-24 08:15AM	Is Bluebird Bio Stock a Buy? (Motley Fool) -6.36%
Apr-13-24 04:22PM	Better Buy: Bluebird Bio Vs. Novavax (Motley Fool)
Apr-11-24 08:30AM	Is This Beaten-Down Stock a Good Acquisition Target? (Motley Fool)
08:00AM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 11:33AM	bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:20AM	Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-27-24 11:37AM	bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates (Zacks) +13.75%
10:00AM	Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline (Zacks)
Mar-26-24 07:01AM	bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -11.76%
Mar-25-24 04:05PM	bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call (Business Wire)
Mar-19-24 07:44AM	bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up (Zacks)
Mar-18-24 06:05PM	Why Bluebird Bio Stock Flew Higher Than the Market Today (Motley Fool)
08:00AM	bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital (Business Wire)
Mar-13-24 07:50AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Mar-11-24 08:00AM	bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy (Business Wire) -7.33%
Mar-05-24 06:56PM	Why Bluebird Bio Stock Dived Into the Red on Tuesday (Motley Fool) -9.15%
Jan-27-24 07:28AM	If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today (Motley Fool)
05:27AM	5 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-10-24 06:55AM	2 Red Flags for Bluebird Bio Stock (Motley Fool)
Jan-08-24 08:00AM	bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook (Business Wire)
Jan-04-24 03:32PM	Bluebirds Plans to Win in Sickle Cell Come Into Focus (The Wall Street Journal) +5.84%
Jan-03-24 07:15AM	Better Risky Investment: Bluebird Bio vs. Shiba Inu (Motley Fool) -6.80%
Jan-02-24 08:00AM	bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.52%
Dec-26-23 08:00AM	Should You Invest in Bluebird Bio Right Now? (Motley Fool)
Dec-24-23 07:39AM	If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today (Motley Fool)
Dec-23-23 07:30AM	1 Green Flag and 1 Red Flag for Bluebird Bio Stock (Motley Fool)
Dec-22-23 08:45AM	3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 (Motley Fool)
Dec-20-23 02:23PM	Bluebird Bio Stock Plunges (Barrons.com) -45.68%
01:54PM	Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Heres Why. (Barrons.com)
Dec-19-23 09:41PM	bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (Business Wire) -20.33%
Dec-18-23 04:01PM	bluebird bio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire) -6.73%
Dec-15-23 11:14AM	Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock? (Motley Fool)
Dec-11-23 05:43AM	Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? (Motley Fool) +7.34%
Dec-10-23 12:02PM	Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-09-23 11:31AM	Long-term Follow-up Data From bluebirds Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events (Business Wire)
Dec-08-23 01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal) -40.54%
01:01PM	bluebird bio Details Plans for the Commercial Launch of LYFGENIA Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
12:35PM	bluebird bio Announces FDA Approval of LYFGENIA (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
Dec-07-23 11:30AM	Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue? (Zacks)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colvin Richard A	Chief Medical Officer	Mar 03 '25	Sale	3.92	584	2,289	7,610	Mar 05 04:05 PM
Klima Thomas J	See Remarks	Mar 03 '25	Sale	3.92	500	1,960	7,878	Mar 05 04:05 PM
Obenshain Andrew	President and CEO	Mar 03 '25	Sale	3.92	921	3,610	18,327	Mar 05 04:05 PM
Obenshain Andrew	Officer	Mar 03 '25	Proposed Sale	3.91	921	3,604		Mar 03 05:51 PM
Klima Thomas J	Officer	Mar 03 '25	Proposed Sale	3.91	500	1,957		Mar 03 05:38 PM
Colvin Richard A	Officer	Mar 03 '25	Proposed Sale	3.91	584	2,285		Mar 03 05:22 PM
Klima Thomas J	See Remarks	Feb 03 '25	Sale	7.39	122	902	8,378	Feb 05 04:15 PM
Colvin Richard A	Chief Medical Officer	Feb 03 '25	Sale	7.39	64	473	8,194	Feb 05 04:15 PM
Vittiglio Joseph	Chief Business & Legal Officer	Feb 03 '25	Sale	7.39	238	1,759	4,501	Feb 05 04:14 PM
Obenshain Andrew	President and CEO	Feb 03 '25	Sale	7.39	86	636	18,485	Feb 05 04:14 PM
Obenshain Andrew	Officer	Feb 03 '25	Proposed Sale	7.74	86	665		Feb 03 04:38 PM
Klima Thomas J	Officer	Feb 03 '25	Proposed Sale	7.74	122	944		Feb 03 04:29 PM
Colvin Richard A	Officer	Feb 03 '25	Proposed Sale	7.74	64	495		Feb 03 04:21 PM
Vittiglio Joseph	Officer	Feb 03 '25	Proposed Sale	7.74	238	1,841		Feb 03 04:10 PM
Colvin Richard A	Chief Medical Officer	Jan 06 '25	Sale	9.24	19	176	8,257	Jan 08 04:06 PM
Obenshain Andrew	President and CEO	Jan 06 '25	Sale	9.24	140	1,294	18,571	Jan 08 04:06 PM
Colvin Richard A	Officer	Jan 06 '25	Proposed Sale	8.74	19	166		Jan 07 05:31 PM
Obenshain Andrew	Officer	Jan 06 '25	Proposed Sale	8.74	140	1,223		Jan 06 06:23 PM
Obenshain Andrew	President and CEO	Dec 10 '24	Sale	0.42	971	405	374,247	Dec 12 04:01 PM
Colvin Richard A	Chief Medical Officer	Dec 10 '24	Sale	0.42	2,824	1,178	165,544	Dec 12 04:01 PM
Colvin Richard A	Officer	Dec 10 '24	Proposed Sale	0.45	2,824	1,271		Dec 10 09:51 PM
Obenshain Andrew	Officer	Dec 10 '24	Proposed Sale	0.45	971	437		Dec 10 09:39 PM
Klima Thomas J	See Remarks	Sep 30 '24	Sale	0.53	1,006	529	170,000	Oct 02 04:06 PM
Obenshain Andrew	President and CEO	Sep 30 '24	Sale	0.53	34,780	18,270	375,218	Oct 02 04:06 PM
Obenshain Andrew	Officer	Sep 30 '24	Proposed Sale	0.52	34,780	18,086		Oct 01 03:10 PM
Klima Thomas J	Officer	Sep 30 '24	Proposed Sale	0.52	1,006	523		Oct 01 01:33 PM
Klima Thomas J	See Remarks	Jun 03 '24	Sale	0.97	3,834	3,726	121,006	Jun 04 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLUE

Bluebird bio Inc

Upgrade your FINVIZ experience